Combined gemcitabine and S-1 chemotherapy for treating unresectable hilar cholangiocarcinoma: a randomized open-label clinical trial

Although the combination of cisplatin and gemcitabine (GEM) is considered the standard first-line chemotherapy against unresectable hilar cholangiocarcinoma (HC), its efficacy is discouraging. The present randomized open-label clinical trial aimed to evaluate the efficacy and safety of the GEM plus...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Hao, Zhang, Zheng-Yun, Zhou, Zun-Qiang, Guan, Jiao, Tong, Da-Nian, Zhou, Guang-Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042023/
https://www.ncbi.nlm.nih.gov/pubmed/27058753
http://dx.doi.org/10.18632/oncotarget.8590

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5042023/
https://www.ncbi.nlm.nih.gov/pubmed/27058753
http://dx.doi.org/10.18632/oncotarget.8590

Ejemplares similares